393 related articles for article (PubMed ID: 34060396)
1.
Deb PK; Al-Shar'i NA; Venugopala KN; Pillay M; Borah P
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):869-884. PubMed ID: 34060396
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of alkynylated 1,2,4-oxadiazole/1,2,3-1H-triazole glycoconjugates: Discovering new compounds for use in chemotherapy against lung carcinoma and Mycobacterium tuberculosis.
Melo de Oliveira VN; Flávia do Amaral Moura C; Peixoto ADS; Gonçalves Ferreira VP; Araújo HM; Lapa Montenegro Pimentel LM; Pessoa CDÓ; Nicolete R; Versiani Dos Anjos J; Sharma PP; Rathi B; Pena LJ; Rollin P; Tatibouët A; Nascimento de Oliveira R
Eur J Med Chem; 2021 Aug; 220():113472. PubMed ID: 33940463
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of (E)-5-styryl-1,2,4-oxadiazoles as anti-tubercular agents.
Atmaram Upare A; Gadekar PK; Sivaramakrishnan H; Naik N; Khedkar VM; Sarkar D; Choudhari A; Mohana Roopan S
Bioorg Chem; 2019 May; 86():507-512. PubMed ID: 30776681
[TBL] [Abstract][Full Text] [Related]
4. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.
Wang A; Xu S; Chai Y; Xia G; Wang B; Lv K; Wang D; Qin X; Jiang B; Wu W; Liu M; Lu Y
Bioorg Med Chem; 2022 Jan; 53():116529. PubMed ID: 34861474
[TBL] [Abstract][Full Text] [Related]
6. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and in vitro antituberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,3,4-oxadiazole derivatives.
Sajja Y; Vanguru S; Vulupala HR; Nagarapu L; Perumal Y; Sriram D; Nanubolu JB
Chem Biol Drug Des; 2017 Oct; 90(4):496-500. PubMed ID: 28267891
[TBL] [Abstract][Full Text] [Related]
8. Benzofuroxan Derivatives as Potent Agents against Multidrug-Resistant Mycobacterium tuberculosis.
Fernandes GFS; Campos DL; Da Silva IC; Prates JLB; Pavan AR; Pavan FR; Dos Santos JL
ChemMedChem; 2021 Apr; 16(8):1268-1282. PubMed ID: 33410233
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and Docking Study of Pyrazine Containing 1, 3, 4-Oxadiazoles Clubbed with Substituted Azetidin-2-one: A New Class of Potential Antimicrobial and Antitubercular.
Das R; Mehta DK
Drug Res (Stuttg); 2021 Jan; 71(1):26-35. PubMed ID: 33027823
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Shruthi TG; Eswaran S; Shivarudraiah P; Narayanan S; Subramanian S
Bioorg Med Chem Lett; 2019 Jan; 29(1):97-102. PubMed ID: 30448235
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
Fernandes GFDS; de Souza PC; Marino LB; Chegaev K; Guglielmo S; Lazzarato L; Fruttero R; Chung MC; Pavan FR; Dos Santos JL
Eur J Med Chem; 2016 Nov; 123():523-531. PubMed ID: 27508879
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of novel 5-aryl-2-thio-1,3,4-oxadiazoles and the study of their structure-anti-mycobacterial activities.
Macaev F; Rusu G; Pogrebnoi S; Gudima A; Stingaci E; Vlad L; Shvets N; Kandemirli F; Dimoglo A; Reynolds R
Bioorg Med Chem; 2005 Aug; 13(16):4842-50. PubMed ID: 15993090
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.
Desai NC; Somani H; Trivedi A; Bhatt K; Nawale L; Khedkar VM; Jha PC; Sarkar D
Bioorg Med Chem Lett; 2016 Apr; 26(7):1776-83. PubMed ID: 26920799
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
15. Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis.
Bakal RL; Gattani SG
Eur J Med Chem; 2012 Jan; 47(1):278-82. PubMed ID: 22088956
[TBL] [Abstract][Full Text] [Related]
16. Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme.
Venugopala KN; Chandrashekharappa S; Deb PK; Tratrat C; Pillay M; Chopra D; Al-Shar'i NA; Hourani W; Dahabiyeh LA; Borah P; Nagdeve RD; Nayak SK; Padmashali B; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Haroun M; Shashikanth S; Mohanlall V; Mailavaram R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1472-1487. PubMed ID: 34210233
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
18. Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
Roh J; Karabanovich G; Vlčková H; Carazo A; Němeček J; Sychra P; Valášková L; Pavliš O; Stolaříková J; Klimešová V; Vávrová K; Pávek P; Hrabálek A
Bioorg Med Chem; 2017 Oct; 25(20):5468-5476. PubMed ID: 28835350
[TBL] [Abstract][Full Text] [Related]
19. Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis.
Makane VB; Krishna VS; Krishna EV; Shukla M; Mahizhaveni B; Misra S; Chopra S; Sriram D; Azger Dusthackeer VN; Rode HB
Future Med Chem; 2019 Mar; 11(6):499-510. PubMed ID: 30892944
[TBL] [Abstract][Full Text] [Related]
20. Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations.
Zampieri D; Mamolo MG; Laurini E; Fermeglia M; Posocco P; Pricl S; Banfi E; Scialino G; Vio L
Bioorg Med Chem; 2009 Jul; 17(13):4693-707. PubMed ID: 19467603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
